These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33109630)

  • 21. miRNAs in the Regulation of Cancer Immune Response: Effect of miRNAs on Cancer Immunotherapy.
    Pottoo FH; Iqubal A; Iqubal MK; Salahuddin M; Rahman JU; AlHajri N; Shehadeh M
    Cancers (Basel); 2021 Dec; 13(23):. PubMed ID: 34885253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure-Function Analysis of Immune Checkpoint Receptors to Guide Emerging Anticancer Immunotherapy.
    Acúrcio RC; Scomparin A; Conniot J; Salvador JAR; Satchi-Fainaro R; Florindo HF; Guedes RC
    J Med Chem; 2018 Dec; 61(24):10957-10975. PubMed ID: 30020783
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of tumor immune infiltration-associated lncRNAs for improving prognosis and immunotherapy response of patients with non-small cell lung cancer.
    Sun J; Zhang Z; Bao S; Yan C; Hou P; Wu N; Su J; Xu L; Zhou M
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32041817
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CancerResource: a comprehensive database of cancer-relevant proteins and compound interactions supported by experimental knowledge.
    Ahmed J; Meinel T; Dunkel M; Murgueitio MS; Adams R; Blasse C; Eckert A; Preissner S; Preissner R
    Nucleic Acids Res; 2011 Jan; 39(Database issue):D960-7. PubMed ID: 20952398
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Integrating Bioinformatics Strategies in Cancer Immunotherapy: Current and Future Perspectives.
    Washah HN; Salifu EY; Soremekun O; Elrashedy AA; Munsamy G; Olotu FA; Soliman MES
    Comb Chem High Throughput Screen; 2020; 23(8):687-698. PubMed ID: 32338212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. cBinderDB: a covalent binding agent database.
    Du J; Yan X; Liu Z; Cui L; Ding P; Tan X; Li X; Zhou H; Gu Q; Xu J
    Bioinformatics; 2017 Apr; 33(8):1258-1260. PubMed ID: 28011781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.
    O'reilly A; Larkin J
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):647-655. PubMed ID: 28604130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Progress of immune checkpoint LAG-3 in immunotherapy.
    Shan C; Li X; Zhang J
    Oncol Lett; 2020 Nov; 20(5):207. PubMed ID: 32963613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. FcγR-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy.
    Chen X; Song X; Li K; Zhang T
    Front Immunol; 2019; 10():292. PubMed ID: 30863404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy.
    Shaaban M; Othman H; Ibrahim T; Ali M; Abdelmoaty M; Abdel-Kawi AR; Mostafa A; El Nakeeb A; Emam H; Refaat A
    Curr Cancer Drug Targets; 2020; 20(6):429-460. PubMed ID: 32321404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recent progress in therapeutic antibodies for cancer immunotherapy.
    Lee A; Sun S; Sandler A; Hoang T
    Curr Opin Chem Biol; 2018 Jun; 44():56-65. PubMed ID: 29885949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
    Song H; Yang P; Huang P; Zhang C; Kong D; Wang W
    Theranostics; 2019; 9(8):2299-2314. PubMed ID: 31149045
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Checkpoint Receptors and Molecules for Therapeutic Modulation of Natural Killer Cells.
    Kim N; Kim HS
    Front Immunol; 2018; 9():2041. PubMed ID: 30250471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ILT4 functions as a potential checkpoint molecule for tumor immunotherapy.
    Gao A; Sun Y; Peng G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):278-285. PubMed ID: 29649510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety.
    Azoury SC; Straughan DM; Shukla V
    Curr Cancer Drug Targets; 2015; 15(6):452-62. PubMed ID: 26282545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape.
    Osipov A; Saung MT; Zheng L; Murphy AG
    J Immunother Cancer; 2019 Aug; 7(1):224. PubMed ID: 31439034
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Checkpoint-modulating immunotherapies in tumor treatment: Targets, drugs, and mechanisms.
    Sun L; Chen L; Li H
    Int Immunopharmacol; 2019 Feb; 67():160-175. PubMed ID: 30553199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.